Oct 26 (Reuters)-
Kainos Laboratories Inc
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2015 Sep 30, 2014 Mar 31, 2016
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 2.58 2.72 5.30
(-5.3 pct) (-2.1 pct) (-3.2 pct)
Operating 214 mln 173 mln 410 mln
(+23.7 pct) (+24.7 pct) (+2.1 pct)
Recurring 223 mln 170 mln 413 mln
(+31.2 pct) (+25.3 pct) (+5.2 pct)
Net 156 mln 106 mln 280 mln
(+47.6 pct) (+19.3 pct) (+21.6 pct)
EPS 35.96 yen 23.87 yen 65.57 yen
Ann Div 12.50 yen 12.50 yen
-Q2 div NIL NIL
-Q4 div 12.50 yen 12.50 yen
NOTE - Kainos Laboratories Inc is a manufacturer of clinical reagents for biochemical and immune serum studies.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4556.T
((Tokyo Headline News Desk +813 6441 1812))